Psilos seeks to be the lead investor in companies that have:
In keeping with our investment philosophy, we look for companies offering products and services that advance the effective operation of the healthcare economy -- where cost savings and enhanced quality of medical outcomes combine in a system that aligns the incentives of patients, payers and providers.
Investment Stage: We focus intently on investing at the stage in a company’s development where the clinical, technology and, often, initial adoption risk has passed. For Psilos, this typically (but not always) involves investment in the second or third institutional rounds (usually "Series B" and later). The companies in which we invest are typically either already selling their product in the marketplace or are within a year or so of market launch. In the healthcare services area, we will invest in companies that can demonstrate an ability to achieve positive cash flow within 12-18 months. In the healthcare IT area, we are looking for companies that have had successful beta launches of their products, at a minimum, and will be in the market with production software within 12-18 months. In the medical technology area, we seek out companies that have meaningful amounts of human clinical data in hand, which have obtained or are close to obtaining FDA approval and are no more than 12-18 months from launch. Of course, Psilos will also invest in companies that have surpassed these milestones and are later in their development. We view our sweet spot as those healthcare companies that have seeded initial demand in the market for their products and are seeking capital to finance growth and expansion.
Investment Size: Psilos typically invests between $8-$15 million initially into companies, with an expectation of investing up to $20-$25 million over the life of an investment.
Investment Geography: United States.
Submit A Business Plan: Click Here to Submit your business plan to Psilos.